New Hismanal Labelling Warns Of Drug Interaction Complications
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




New Hismanal Labelling Warns Of Drug Interaction Complications

WASHINGTON, MD -- February 10, 1998 -- The United States Food and Drug Administration (FDA) is warning consumers and health care providers about new safety information regarding Janssen Pharmaceutica’s prescription antihistamine Hismanal (astemizole) and its potential effects when combined with other drugs.

This warning is being issued in conjunction with the addition of more information in the product label about cardiovascular adverse events, new potentially serious drug interactions and rare reports of anaphylaxis, a potentially life-threatening reaction.

According to the FDA, Hismanal is associated with life-threatening irregular heart rhythms when taken with certain other drugs and when used at higher than the recommended dose. The new labelling will include a specific warning against combining Hismanal with certain drugs such as the hypertension drug, Posicor (mibefradil dihydrochloride) and the antibiotics, Biaxin (clarithromycin) and TAO (troleandomycin).
The new labelling also warns against using Hismanal with a number of other drugs, including: HIV protease inhibitors such as Crixivan (indinavir), Norvir (ritonavir), Invirase (saquinavir) and Viracept (elfinavir); serotonin reuptake inhibitors such as Prozac (fluoxetine), Luvox (fluvoxamine), Zoloft (sertraline), Serzone (nefazodone) and Paxil (paroxetine); and the antiasthma medication Zyflo (zileuton).

Additionally, the label now recommends that Hismanal should not be taken with grapefruit juice. Research has shown that grapefruit juice can interfere with the body's handling and metabolism of Hismanal.

The new labelling also warns against prescribing Hismanal in patients with liver disorders.

More information on: Hismanal, Janssen Pharmaceutica

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities